Biomaterials Asia 2009 Conference Highlights Leading Biomaterials Science in Asia
Oxford, 26 March 2009 – Elsevier announced today, that Biomaterials, the leading journal in the field of biomaterials science, will host Biomaterials Asia 2009 in Hong Kong from April 5-8 to highlight the latest Asian research developments, institutions, and individuals in biomaterials science.
Under the chairmanship of Professor David Williams, Editor-in-Chief of Biomaterials, the conference program will focus on the interface between advanced materials science and biological science, bringing the latest expertise in advanced medical engineering, clinical sciences and regenerative medicine under one roof.
This event, with keynote speakers drawn from the world’s best scientists, will provide an unparalleled opportunity for researchers, technologists and clinicians in the fields of bioengineering, medical device technology, pharmaceutical science, tissue engineering and biomaterials science to explore and debate the latest scientific developments, translational science and commercial applications. Conference sessions will be modeled after the scientific sections defined by Biomaterials, the world’s foremost journal in the field with an Impact Factor of 6.262.
“Biomaterials science is concerned with the reconstruction of the human body through the use of implantable medical devices and the technologies of regenerative medicine,” remarked Professor Williams, conference Chair and Editor-in-Chief of Biomaterials, “Biomaterials Asia 2009 will enable some of the best laboratories and hospitals across Asia to showcase many of the topical technologies that are responsible for significant advances in health care, including stem cell science, nanomedicine and tissue engineering.”
“Research laboratories and hospitals across Asia are making such a tremendous contribution to the latest developments in biomaterials, that we are delighted to set a precedent with this unique forum,” added YS Chi, Vice Chairman at Elsevier, who will officially open the conference on April 5th, “Biomaterials Asia enables us to honor world class scientists and clinicians across Asia who are making critical contributions to global health care.”
# # #
Notes to Editors:
Seeram Ramakrishnam, Vice President, National University of Singapore and Tim Pratt, Executive VP and General Counsel, Boston Scientific will also be at the opening ceremony, alongside Professor Williams and YS Chi.
Highlights of the program include Rocky Tuan (NIH, USA) who will be talking about adult stem cells and nanomaterials in skeletal tissue engineering and regenerative medicine; and Si-Shen Feng from the National University of Singapore, discussing nanoparticles of biodegradable polymers for diagnosis and treatment of cancer.
For more information please see the full program online.
Biomaterials is the leading international journal covering the science and application of biomaterials and associated medical devices. It is the aim of the journal to provide a peer-reviewed forum for the publication of original papers and authoritative review papers dealing with the most important issues facing the use of materials in clinical practice. The journal is relevant to all applications of biomaterials including implantable medical devices, tissue engineering and drug delivery systems.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai’s Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.
Name Deborah Logan
Phone +44(0)1865 843061